Skip to main content

Advertisement

SpringerLink
Log in

Consolidation/maintenance chemotherapy for ovarian cancer

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

A recently reported randomized trial has demonstrated that administration of single-agent paclitaxel to women with advanced ovarian cancer who attain a clinically defined complete response to platinum/paclitaxel-based chemotherapy can substantially improve progression-free survival. Whether this strategy will improve overall survival in this clinical setting remains uncertain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Omura GA, Morrow CP, Blessing JA, et al.: A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer 1983, 51:783–789.

    Article  PubMed  CAS  Google Scholar 

  2. Fisher B, Carbone P, Economou SG, et al.: l-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: a report of early findings. N Engl J Med 1975, 292:117–122.

    Article  PubMed  CAS  Google Scholar 

  3. Hakes TB, Chalas E, Hoskins WJ, et al.: Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992, 45:284–289.

    Article  PubMed  CAS  Google Scholar 

  4. Lambert HE, Rustin GJS, Gregory WM, Nelstrop AE: A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma: a North Thames Ovary Group study. Ann Oncol 1997, 8:327–333.

    Article  PubMed  CAS  Google Scholar 

  5. Bertelsen K, Jakobsen A, Stroyer I, et al.: A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA)1. Gynecol Oncol 1993, 49:30–36.

    Article  PubMed  CAS  Google Scholar 

  6. Greene MH, Boice JD Jr, Greer BE, et al.: Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. N Engl J Med 1982, 307:1416–1421.

    Article  PubMed  CAS  Google Scholar 

  7. Reimer RR, Hoover R, Fraumeni JF Jr, Young RC: Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med 1977, 297:177–181.

    Article  PubMed  CAS  Google Scholar 

  8. Tolba KA, Deliargyris EN: Cardiotoxicity of cancer therapy. Cancer Invest 1999, 17:408–422.

    Article  PubMed  CAS  Google Scholar 

  9. McGuire WP, Hoskins WJ, Brady MF, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1–6. This study defined the role of paclitaxel as a component of primary chemotherapy for ovarian cancer.

    Article  PubMed  CAS  Google Scholar 

  10. Piccart MJ, Bertelsen K, James K, et al.: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000, 92:699–708.

    Article  PubMed  CAS  Google Scholar 

  11. Browder T, Butterfield CE, Kraling BM, et al.: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000, 60:1878–1886.

    PubMed  CAS  Google Scholar 

  12. Tuxen MK, Soletormos G, Dombernowsky P: Serum tumour marker CA 125 in monitoring of ovarian cancer during firstline chemotherapy. Br J Cancer 2001, 84:1301–1307.

    Article  PubMed  CAS  Google Scholar 

  13. Rustin GJS, Nelstrop AE, Tuxen MK, Lambert HE: Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group study. Ann Oncol 1996, 7:361–364.

    PubMed  CAS  Google Scholar 

  14. Gershenson DM, Mitchell MF, Atkinson N, et al.: The effect of prolonged cisplatin-based chemotherapy on progressionfree survival in patients with optimal epithelial ovarian cancer: ‘maintenance’ therapy reconsidered. Gynecol Oncol 1992, 47:7–13.

    Article  PubMed  CAS  Google Scholar 

  15. Eltabbakh GH, Piver MS, Hempling RE, et al.: Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol 1998, 71:190–195.

    Article  PubMed  CAS  Google Scholar 

  16. Vasey P, on behalf of the Scottish Gynaecologic Cancer Trials Group: Preliminary results of the SCOTROC trial: a phase III comparison of paclitaxel-carboplatin (PC) and docetaxel-carboplatin (DC) as first-line chemotherapy for stage Ic-IV epithelial ovarian cancer (EOC) [abstract]. Proc ASCO 2001, 20:202a.

    Google Scholar 

  17. Rowinsky EK, Donehower RC: Paclitaxel (taxol). N Engl J Med 1995, 332:1004–1014.

    Article  PubMed  CAS  Google Scholar 

  18. Trimble EL, Adams JD, Vena D, et al.: Paclitaxel for platinumrefractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993, 11:2405–2410.

    PubMed  CAS  Google Scholar 

  19. Markman M, Hakes T, Barakat R, et al.: Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center Protocol 9103: paclitaxel in refractory ovarian cancer. J Clin Oncol 1996, 14:796–799. This study suggested that prolonged paclitaxel may have a favorable impact on survival in far advanced platinum-refractory ovarian cancer.

    PubMed  CAS  Google Scholar 

  20. Rohl J, Kushner D, Markman M: Chronic administration of single-agent paclitaxel in gynecologic malignancies. Gynecol Oncol 2001, 81:201–205.

    Article  PubMed  CAS  Google Scholar 

  21. Markman M, Liu PY, Wilczynski S, et al.: Phase 3 randomized trial of 12 versus 3 months of single-agent paclitaxel in patients with advanced ovarian cancer who attained a clinically defined complete response to platinum/paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003, 21:2460–2465. This study demonstrated the substantial impact of 12 months of singleagent consolidation/maintenance paclitaxel in ovarian cancer.

    Article  PubMed  CAS  Google Scholar 

  22. McGuire WP, Rowinsky EK, Rosenshein NB, et al.: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989, 111:273–279.

    PubMed  CAS  Google Scholar 

  23. Thigpen JT, Blessing JA, Ball H, et al.: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994, 12:1748–1753.

    PubMed  CAS  Google Scholar 

  24. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al.: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994, 12:2654–2666.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, 44195, Cleveland, OH, USA

    Maurie Markman MD

Authors
  1. Maurie Markman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Markman, M. Consolidation/maintenance chemotherapy for ovarian cancer. Curr Oncol Rep 5, 454–458 (2003). https://doi.org/10.1007/s11912-003-0005-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-003-0005-y

Keywords

Search

Navigation